Additional file 1: Figure S1. of Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain M. Sanchez-Luna R. Burgos-Pol I. Oyagüez J. Figueras-Aloy M. Sánchez-Solís F. Martinón-Torres X. Carbonell-Estrany 10.6084/m9.figshare.c.3907168_D1.v1 https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_Figure_S1_of_Cost-utility_analysis_of_Palivizumab_for_Respiratory_Syncytial_Virus_infection_prophylaxis_in_preterm_infants_update_based_on_the_clinical_evidence_in_Spain/5509060 Curve fitting to get the palivizumab effect on recurrent wheezing over 61 years by using RR values from the literature. (DOCX 19 kb) 2017-10-17 05:00:00 Cost-effectiveness Preterm infants Palivizumab RSV infection Recurrent wheezing